CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,959 enrolled
Drug / intervention
Rizatriptan 5 mg +2 moredrug
Likely dose
Rizatriptan 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01286207
NCT01286207Phase 3Completed
CompareCT.gov

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)

Organon and Co·interventional·Posted Jan 31, 2011·Updated Feb 3, 2022

In Brief

A Phase 3 clinical trial evaluating Rizatriptan 5 mg, Rizatriptan 10 mg, and 1 other intervention for Migraine Disorders. Completed, enrolled 1,959 participants.

Detailed Summary

This record describes pooled data for three extension studies: MK-0462-022 (NCT00897949); MK-0462-025 (NCT00899379); and MK-0462-029 (NCT00897104). These studies examined the long-term safety and efficacy of rizatriptan used for the treatment of acute migraine and migraine recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2011
Enrollment StartMar 1, 1995
Primary CompletionMay 1, 1997
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.4 years ago

Interventions

Rizatriptan 5 mgdrug

Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)

Rizatriptan 10 mgdrug

Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)

Standard Caredrug

Active standard care